专利检索 ap:("Eisai R&D Management Co., Ltd.") AND inv:"Daniel Aird" 第 1 页

1.

发明授权
Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use 有权

公开(公告)号：US11524009B2

公开(公告)日：2022-12-13

申请号：US16760313

申请日：2018-10-30

申请人： Eisai R&D Management Co., Ltd.

发明人： Daniel Aird , Laura Corson , Ping Zhu , Markus Warmuth , Silvia Buonamici , Peter Gerard Smith , Peter Fekkes

IPC分类号： A61K31/496 , A61P35/00 , A61K31/05 , A61K31/11 , A61K31/166 , A61K31/343 , A61K31/352 , A61K31/395 , A61K31/404 , A61K31/426 , A61K31/4355 , A61K31/4725 , A61K31/495 , A61K31/5355

摘要： The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.